MoonLake Immunotherapeutics Business Summary

As of February 16, 2026, MoonLake Immunotherapeutics (MLTX) operates as a clinical-stage biopharmaceutical company that generates value through the development and future commercialization of its proprietary Nanobody® platform. The company currently reports zero product revenue, with its financial model centered on achieving clinical milestones and securing regulatory approvals to transition into a commercial-stage entity. MoonLake’s primary business segments are focused on inflammatory skin and joint diseases, specifically targeting Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), and Palmoplantar Pustulosis (PPP). Its lead asset, sonelokimab (SLK), is a trivalent IL-17A/F inhibitor designed to offer superior tissue penetration and deeper clinical response compared to traditional monoclonal antibodies. Direct competitors include UCB (Bimzelx), Novartis (Cosentyx), and Eli Lilly (Taltz), as well as emerging players like Affibody Medical (izokibep). MoonLake differentiates itself by utilizing a smaller, ~40 kDa nanobody format that enables enhanced enrichment in deep skin and joint tissues, positioning SLK as a potential best-in-class therapy for refractory patients who fail first-generation IL-17 inhibitors. The leadership team is anchored by Co-founder and CEO Dr. Jorge Santos da Silva, a former Senior Partner at McKinsey & Company with extensive experience in biopharma strategy and product launches. He is joined by Co-founder and Chief Scientific Officer (CSO) Dr. Kristian Reich, a world-renowned dermatologist and academic who previously served as a lead investigator for numerous blockbuster immunology trials. The executive suite also includes CFO Matthias Bodenstedt, formerly of McKinsey and specialized in corporate finance, and Chief Medical Officer (CMO) Dr. Benjamin Porter-Brown, who brings deep clinical development expertise from roles at major pharmaceutical firms. The company is supported by a high-pedigree board of directors, including Chairman Simon Sturge (formerly of Merck KGaA and LumiraDx) and notable institutional backing from BVF Partners L.P., which remains a significant shareholder. This leadership group combines deep scientific specialization in the IL-17 pathway with the commercial expertise necessary to navigate the planned Biologics License Application (BLA) submission for HS in the second half of 2026.